SCHEMBL7433412

SCHEMBL7433412

[CH2]CCCN1CCN(c2ccccc2OC)CC1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 3/20 0.76
DRD3 P35462 2/20 0.76
HTR1A P08908 3/20 0.74
HTR7 P34969 4/20 0.66
MEN1 O00255 2/20 0.66
KMT2A Q03164 2/20 0.66
ADRA1D P25100 2/20 0.66
ADRA1A P35348 2/20 0.66
ADRA1B P35368 2/20 0.66
CYP1A2 P05177 1/20 0.66
CYP2C9 P11712 1/20 0.66
CYP2C19 P33261 1/20 0.66
HTR2A P28223 2/20 0.64
ALDH1A1 P00352 2/20 0.64
CYP3A4 P08684 1/20 0.64
CYP2D6 P10635 1/20 0.64
ALOX12 P18054 1/20 0.64
HIF1A Q16665 1/20 0.64
HSD17B10 Q99714 1/20 0.64
KDM4E B2RXH2 1/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1388101 0.91 DRD2 (0.75) DRD2DRD3HTR1AHTR7MEN1
SCHEMBL6526368 0.91 DRD2 (0.85) DRD2DRD3HTR1AHTR7MEN1
SCHEMBL1255253 0.87 DRD2 (0.78) DRD2DRD3HTR1AHTR7MEN1
SCHEMBL10414460 0.87 DRD2 (1.00) DRD2DRD3HTR1AHTR7MEN1
SCHEMBL30206503 0.87 DRD2 (0.78) DRD2DRD3HTR1AHTR7MEN1
SCHEMBL10415008 0.86 DRD2 (0.68) DRD2DRD3HTR1AHTR7MEN1
SCHEMBL7821310 0.85 DRD2 (0.76) DRD2DRD3HTR1AHTR7MEN1
SCHEMBL2215388 0.85 DRD2 (0.76) DRD2DRD3HTR1AHTR7MEN1
Hydrochloric Acid SCHEMBL8980706 0.85 DRD2 (0.76) DRD2DRD3HTR1AHTR7MEN1
Hydrochloric Acid SCHEMBL11651993 0.85 DRD2 (0.76) DRD2DRD3HTR1AHTR7MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012050884-A2 CARDIAC GLYCOSIDES ARE POTENT INHIBITORS OF INTERFERON-BETA GENE EXPRESSION PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2012-04-19 WO claimed
US-5580871-A FOR TREATMENT OF CONGESTIVE HEART FAILURE THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) 1996-12-03 US claimed
US-11963964-B2 Small molecules for mouse satellite cell proliferation PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2024-04-23 US disclosed
US-20220054499-A1 SMALL MOLECULES FOR MOUSE SATELLITE CELL PROLIFERATION PRESIDENT AND FELLOWS OF HARVARD COLLEGE 2022-02-24 US disclosed
US-11026952-B2 Small molecules for mouse satellite cell proliferation PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2021-06-08 US disclosed
US-10660902-B2 Method of increasing satellite cell proliferation with an HDAC inhibitor PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2020-05-26 US disclosed
EP-3411040-A1 SMALL MOLECULES FOR MOUSE SATELLITE CELL PROLIFERATION President and Fellows of Harvard College (US) 2018-12-12 EP disclosed
US-20180153902-A1 SMALL MOLECULE SCREENING FOR MOUSE SATELLITE CELL PROLIFERATION HOWARD HUGHES MEDICAL INSTITUTE 2018-06-07 US disclosed
WO-2017136480-A1 SMALL MOLECULES FOR MOUSE SATELLITE CELL PROLIFERATION PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2017-08-10 WO disclosed
EP-2646107-A2 AGENT DELIVERY SYSTEMS FOR SELECTIVE NEUROMODULATION Spinal Modulation Inc. (US) 2013-10-09 EP disclosed
WO-2012174537-A2 SMALL MOLECULE SCREENING FOR MOUSE SATELLITE CELL PROLIFERATION PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2012-12-20 WO disclosed
WO-2012075337-A2 DIRECTED DELIVERY OF AGENTS TO NEURAL ANATOMY SPINAL MODULATION, INC. (US) 2012-06-07 WO disclosed
US-5580871-A FOR TREATMENT OF CONGESTIVE HEART FAILURE THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) 1996-12-03 US disclosed
US-5432188-A Treating congestive heart failure THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) 1995-07-11 US disclosed
US-5166147-A Congestive heart failure THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) 1992-11-24 US disclosed
US-4895846-A CARDIOVASCULAR DISORDERS BRISTOL-MYERS COMPANY (US) 1990-01-23 US disclosed
US-4755512-A Pharmaceutically useful dihydropyridinyldicarboxylate amides and esters incorporating arylpiperazinylalkyl moities BRISTOL-MYERS COMPANY (US) 1988-07-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11026952-B2 Small molecules for mouse satellite cell proliferation MKI67, MYLK2, MYH2 DRD2 4820/4885DRD3 4812/4885HTR1A 4523/4885
US-10660902-B2 Method of increasing satellite cell proliferation with an HDAC inhibitor HDAC4, HDAC1, HDAC5 DRD2 4880/4885DRD3 4860/4885HTR1A 4008/4885
US-20220054499-A1 SMALL MOLECULES FOR MOUSE SATELLITE CELL PROLIFERATION MKI67, MYLK2, MYH2 DRD2 4820/4885DRD3 4812/4885HTR1A 4523/4885
US-20180153902-A1 SMALL MOLECULE SCREENING FOR MOUSE SATELLITE CELL PROLIFERATION MKI67, MYLK2, MYH2 DRD2 4802/4885DRD3 4768/4885HTR1A 4499/4885
US-11963964-B2 Small molecules for mouse satellite cell proliferation MKI67, MYLK2, MYH2 DRD2 4820/4885DRD3 4812/4885HTR1A 4523/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.